Metformax Combi

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformax Combi, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Metformax Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. With a focus on regulatory compliance, GNH USA ensures product integrity throughout the supply chain.

Metformax Combi is indicated for the management of type 2 diabetes mellitus in adults, providing dual pathway glucose control that complements diet and exercise.

Type 2 diabetes mellitus: lowers fasting and postprandial blood glucose levels. HbA1c reduction: improves glycated hemoglobin values to achieve target glycemic control. Combination therapy: offers dual mechanism for patients inadequately controlled on monotherapy. Adjunct to diet and exercise: improves glycemic outcomes when combined with lifestyle modifications. Inadequate response to metformin alone: provides additional glucose lowering via DPP‑4 inhibition.

Metformax Combi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Metformax Combi, clinicians should consider several precautionary measures to ensure patient safety.

Renal function: assess creatinine clearance and avoid use in severe renal impairment. Hepatic impairment: use with caution and monitor liver enzymes. Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Blood glucose monitoring: adjust dose based on glycemic response to prevent hypoglycemia. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformax Combi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction, increasing metformin accumulation. - Insulin or sulfonylureas: combined use heightens risk of severe hypoglycemia. - Cimetidine: can raise metformin plasma concentrations. - Rifampin: reduces sitagliptin exposure, diminishing glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: concurrent use can impair renal function, requiring dose adjustment. - Beta‑blockers: may mask hypoglycemia symptoms.